13 melanoma patients

Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial.

Most patients having received the vaccine already demonstrated broad responses to numerous peptides prior vaccination. Significantly enhanced responses to several peptides and occurrence of new responses was seen in 6 patients, 5 of which were vaccinated with E/L-S+ DC. These data provide evidence for a superior immunopotency of E/L-selectin expressing DC.

• molecule type
• melanoma antigen MAGE-3,
• selectin,
• survivin,
• Melan A

• organism type
• Homo sapiens

created over 15 years ago (16 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]